Market Overview

Bristol-Myers Presents Data on Nivolumab from Lung Cancer Cohort of Phase 1 Study at 15th World Conference on Lung Cancer

Bristol-Myers
Squibb Company (NYSE: BMY) today announced long-term follow-up
results (median follow up of 20.3 months) from the lung cancer cohort
(n=129) of the expanded Phase 1 dose-ranging study (003) of nivolumab,
an investigational PD-1 immune checkpoint inhibitor. Results showed
sustained activity in heavily pre-treated patients with non-small-cell
lung cancer (NSCLC) as defined by one- and two-year survival rates of
42% and 24%, respectively, across dose cohorts. These data, which are
based on Kaplan-Meier estimates, will be presented on October 29 at the
World Conference on Lung Cancer (Abstract # MO18.03).

“Our goal with immuno-oncology is to change survival expectations and
the way patients live with cancer,” said Michael Giordano, senior vice

See full press release

Posted-In: News Guidance Contracts Legal Global

 

Related Articles (BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters